ICYMI: Taking CAR-T for a Test Drive
When the ACR Convergence 2024 abstract site went live, the first query I typed into the search bar was, “CAR-T.” I consider myself a CAR-T skeptic and would be surprised if the magical results fro
Off-Label Use of JAK Inhibitors in Orphan Diseases and Other Conditions?
The issues surrounding publication bias are real.
Several positive, uncontrolled case series suggest that JAK inhibitors (JAKi) may be effective in:
Why should rheumatologists care about aging?
As a herald to what was to come in Washington, the publication of the Lancet Rheumatology series on aging coming just days before ACR24 set the stage for the “grey tsunami” of geriatric rheumatology that was to follow.
ICYMI: Taking AI Out of AutoImmunity: Predicting disease before it develops
Autoantibodies play a crucial role in diagnosing and classifying autoimmune and connective tissue disorders. However, the predictive value of a positive antinuclear antibody (ANA) test—especially in the absence of other clinical symptoms—remains a challenge.
Taking AI Out of AutoImmunity: Predicting disease before it develops
Autoantibodies play a crucial role in diagnosing and classifying autoimmune and connective tissue disorders. However, the predictive value of a positive antinuclear antibody (ANA) test—especially in the absence of other clinical symptoms—remains a challenge.
Taking CAR-T for a Test Drive
When the ACR Convergence 2024 abstract site went live, the first query I typed into the search bar was, “CAR-T.” I consider myself a CAR-T skeptic and would be surprised if the magical results fro
ACR 2024 - Day 1 Report
ACR Convergence 2024 opened today with a full slate of presentations, posters and specialty meetings. The meeting began with a flip: the plenary sessions started at 9AM and the poster session began at 1030 AM. Below are some of the highlights from day one in Washington, DC. Anoth
ACR 2024 - Featured Industry Presentations
ACR24 Begins today. Many of the great presentations for this meeting come from industry sponsored clinical trials and reports. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.
ACR24 Preview Podcast (11.15.2024)
ACR 2024 starts tomorrow. Here are a few previews of abstracts to be presented, along with my recommendations of sessions you don’t want to miss.
Previews:
Dr. Quotes (11.8.2024)
Dr. Jack Cush reviews the news and journal reports from this past week from RheumNow.com.
COVID-19 and Long-Term Risk of Autoimmune and Autoinflammatory Disorders
A Korean population based study found that people infected with COVID-19, especially severe COVID-19, had an increased risk of autoimmune and autoinflammatory connective tissue disorders.
EULAR Review of Lifestyle Improvements for Rheumatic Patients
A EULAR taskforce has evaluated the effect of lifestyle behaviors in rheumatic and musculoskeletal diseases (RMDs) and concluded that there is moderate evidence for a small benefit for certain dietary components, but overall, high-level evidence regarding dietary exposure
Social
#EULAR2025 Abstr#OP0074 Manufacturing time for CAR-T can be a hindrance. Preliminary study (N=10 #SLE patients) of CD19/BCMA dual-targeting CAR-T developed on the novel FasTCAR-T platform with next-day manufacturing, showed promising efficacy and safety signals @RheumNow https://t.co/bgF04qe9C7
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
6 months ago
#EULAR2025 Abstr#OP0032 “Off-the-Shelf” iPSC-derived CAR-T is coming soon! Promising data on 5 #SLE patients in Phase 1. Advantages over autologous/allogenic:
-No apheresis
-No conditioning chemo
-Shorter hospital stays ~3days
-Ability to redose in partial responder
@RheumNow https://t.co/qimC94pVU1
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
6 months ago
#AI can be a valuable tool, but needs to be reliable. Lupus100 and #lupusGPT created with vetted sources,
#Easylupus is condensed, even more easy to read
It's better to ask your patients to use it as a reliable source!
#EULAR2025 @RheumNow https://t.co/FbYYm1dB8E
Links:
Bella Mehta @bella_mehta ( View Tweet )
6 months ago
Psychological Bulletin has published that invalidating (gaslighting) pts Sxs can have harmful consequences. Includes pts dx w/ Ehlers-Danlos, endometriosis, fibromyalgia, ME/CFS, POTS, Gulf War, IBS, long Covid, multiple chemical sensitivity, SLE, and vulvodynia.
Dr. John Cush @RheumNow ( View Tweet )
6 months 1 week ago
Psychological Bulletin has published that invalidating (gaslighting) pts Sxs can have harmful consequences. Includes pts dx w/ Ehlers-Danlos, endometriosis, fibromyalgia, ME/CFS, POTS, Gulf War, IBS, long Covid, multiple chemical sensitivity, SLE, and vulvodynia.
Dr. John Cush @RheumNow ( View Tweet )
6 months 1 week ago
Belimumab in SLE with Mucocutaneous or Vasculitis Findings
A post hoc analysis of a belimumab (BEL) inn systemic lupus erythematosus (SLE) study showed lupus mucocutaneous and vasculitic manifestations improve with BEL and standard care.
https://t.co/BlYWKLJPdb
Dr. John Cush @RheumNow ( View Tweet )
6 months 1 week ago
🔺CTD-ILD radiological signs to look out for 👀
#CTD #ILD #UIP #NSIP #Fibrosis #scleroderma #systemicsclerosis #Sjogrens #Lupus
By @IlliasulK https://t.co/hHupTz0bCy
Dr Gurdeep S Dulay @gurdeep_dulay ( View Tweet )
6 months 2 weeks ago
Shifting the Management Paradigm for SLE and Lupus Nephritis
The paradigm for treating patients with systemic lupus erythematosus (SLE) is rapidly shifting and our patients will surely benefit with improved outcomes.
https://t.co/idxMBTyTwp https://t.co/unxmjVst3D
Dr. John Cush @RheumNow ( View Tweet )
6 months 2 weeks ago
Single center study of 1538 #SLE pts found 2.2% w/ lupus mesenteric vasculitis (LMV) - 39 LMV episodes in 31 pts - 2/3 had Nausea, vomiting, diarrhea & abdominal pain (~15% peritoneal irritation) & had active Dz (renal, Skin, Heme). LMV responded to steroids & https://t.co/AkuvCl6nG6
Dr. John Cush @RheumNow ( View Tweet )
6 months 2 weeks ago
>200 genes 🧬 implicated in #SLE
Complex indeed!
And
▶️ 7 clusters of signalling pathways
So we have to have many Rx options
Ab patterns vary
LN flares can have v diff pathways between Pts
#LUPUS2025 @RheumNow
Unravelling #LUPUS2026 https://t.co/LEKN363194
Links:
Janet Pope @Janetbirdope ( View Tweet )
6 months 2 weeks ago
